Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413770 | 0.87 | HTT (0.68) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL8205371 | 0.86 | HTT (0.67) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL2139876 | 0.84 | HTT (0.65) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL2139878 | 0.84 | HTT (0.65) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL11317170 | 0.84 | HTT (0.65) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL6605706 | 0.84 | HTT (0.68) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL18254066 | 0.83 | HTT (0.81) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL8437001 | 0.83 | HTT (0.63) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL15697210 | 0.83 | HTT (0.63) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL2037306 | 0.83 | SLC1A3 (0.70) | HTTLMNASMN1; SMN2FOLH1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | HTT 1061/4885LMNA 3453/4885SMN1; SMN2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.